Brentuximab Vedotin: Uses, Dosage, Side Effects & Administration

Summary of Key Points

Brentuximab vedotin is a prescription medication used to treat specific types of lymphoma, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It works by targeting cancer cells and delivering a chemotherapy agent directly to them. This medication is administered through intravenous (IV) infusion, typically in a healthcare setting. Always consult your healthcare provider before starting or adjusting your treatment plan.

Names of the Medication

US Brand Name: Adcetris

Generic Name: Brentuximab vedotin

The generic name refers to the active ingredient in the medication and is often listed alongside the brand name for clarity.

Pharmacologic Category

1. Antineoplastic Agent
2. Antibody-Drug Conjugate
3. CD30-Directed Antibody

Brentuximab Vedotin Dosage Guidelines

Brentuximab vedotin is prescribed for various types of lymphoma in adults. The dosing schedule may vary depending on the specific condition being treated. Below are the typical dosing guidelines:

1. Hodgkin Lymphoma: 1.8 mg/kg as an IV infusion every three weeks, typically for up to 16 cycles.
2. Systemic Anaplastic Large Cell Lymphoma (sALCL): 1.8 mg/kg every three weeks. The duration of treatment depends on the patient’s response.
3. Peripheral T-Cell Lymphoma (PTCL): 1.8 mg/kg every three weeks as an IV infusion. Treatment length is determined by the patient’s response.
4. Non-Hodgkin Lymphoma (NHL): 1.8 mg/kg every three weeks, typically for up to 16 cycles.
5. Cutaneous T-Cell Lymphoma (CTCL): 1.8 mg/kg every three weeks, with treatment continuing based on the patient’s response.
6. Relapsed/Refractory Hodgkin Lymphoma: 1.8 mg/kg every three weeks, usually for up to 16 cycles.
7. Relapsed/Refractory Systemic ALCL: 1.8 mg/kg every three weeks. The duration of treatment depends on the patient’s response.
8. Primary Mediastinal B-Cell Lymphoma (PMBCL): 1.8 mg/kg every three weeks, typically for up to 16 cycles.
9. Diffuse Large B-Cell Lymphoma (DLBCL): 1.8 mg/kg every three weeks, usually for up to 16 cycles.
10. Mantle Cell Lymphoma (MCL): 1.8 mg/kg every three weeks, with treatment continuing based on the patient’s response.

Always consult your healthcare provider before making any changes to your dosage. If you have questions about your treatment plan, consider scheduling a telemedicine appointment with one of our providers to explore your options.

Dosage Forms and Strengths

Injection: Powder for solution, 50 mg per vial

Brentuximab Vedotin Administration Guidelines

Brentuximab vedotin is administered as an intravenous (IV) infusion, typically in a healthcare setting such as a hospital or clinic. The infusion process usually takes about 30 minutes. Your healthcare provider will monitor you during and after the infusion to check for potential side effects. It is crucial to follow your provider’s instructions and attend all scheduled appointments to ensure the medication works effectively.

Brentuximab Vedotin Side Effects

Like all medications, Brentuximab vedotin may cause side effects. Some are common, while others are less frequent but more serious. It’s important to recognize these and contact your healthcare provider if you experience any concerning symptoms.

Common Side Effects

1. Fatigue: Unusual tiredness or weakness.
2. Nausea: A sensation of sickness in the stomach, which may lead to vomiting.
3. Diarrhea: Frequent, loose, or watery bowel movements.
4. Fever: An elevated body temperature, often a sign of infection.
5. Peripheral Neuropathy: Numbness, tingling, or pain in the hands and feet.

Serious Side Effects (Less Common)

1. Infusion Reactions: Symptoms such as rash, difficulty breathing, or swelling during or after the infusion.
2. Severe Infections: A higher risk of serious infections due to a weakened immune system.
3. Liver Problems: Signs include yellowing of the skin or eyes, dark urine, or pain in the upper right abdomen.
4. Lung Problems: Symptoms such as difficulty breathing, coughing, or chest pain.

If you experience any of these side effects, especially the serious ones, contact your healthcare provider immediately. You can also schedule a telemedicine appointment with one of our providers to discuss your symptoms and receive guidance on managing side effects.

Contraindications

A contraindication refers to a specific condition or circumstance in which a medication, such as Brentuximab vedotin, should not be used because it may pose significant risks to the patient. If you have any of the following conditions, Brentuximab vedotin may not be a safe treatment option for you. Your healthcare provider will assess your situation and recommend alternative therapies if necessary.

Hypersensitivity to Brentuximab vedotin: If you have previously experienced an allergic reaction to Brentuximab vedotin or any of its components, taking this medication again could result in severe allergic responses. These may include symptoms such as difficulty breathing, swelling, or hives, which require immediate medical attention.

Concurrent use with Bleomycin: Brentuximab vedotin should not be used in combination with Bleomycin, a chemotherapy drug. This combination significantly increases the risk of severe lung toxicity, which can lead to breathing difficulties and permanent lung damage.

Severe liver impairment: Because Brentuximab vedotin is processed by the liver, individuals with severe liver disease may be unable to metabolize the drug effectively. This can result in increased toxicity and heightened side effects, making the treatment unsafe for these patients.

Drug-to-Drug Interactions

Brentuximab vedotin can interact with other medications, potentially increasing the risk of side effects or reducing its effectiveness. It is essential to inform your healthcare provider about all medications you are currently taking, including prescription drugs, over-the-counter products, and dietary supplements. Below are some notable drug interactions to be aware of:

Ketoconazole (Nizoral): This antifungal medication can raise the levels of Brentuximab vedotin in your body, which may increase the likelihood of side effects.

Rifampin (Rifadin): Commonly prescribed for tuberculosis, Rifampin can decrease the effectiveness of Brentuximab vedotin by speeding up its breakdown in the body.

Phenytoin (Dilantin): This anti-seizure medication may reduce the effectiveness of Brentuximab vedotin by accelerating its metabolism.

Carbamazepine (Tegretol): Another anti-seizure medication, Carbamazepine, can similarly lower the effectiveness of Brentuximab vedotin by increasing the rate at which it is broken down in the body.

Brentuximab vedotin in Pregnancy

Is it safe to take Brentuximab vedotin during pregnancy?

Brentuximab vedotin is not considered safe for use during pregnancy. This medication can harm an unborn baby, potentially leading to birth defects or pregnancy loss. If you are pregnant or planning to become pregnant, it is crucial to discuss this with your healthcare provider. Women of childbearing age should use reliable contraception during treatment with Brentuximab vedotin and for at least 6 months after the final dose. If you become pregnant while taking this medication, contact your healthcare provider immediately to discuss the best course of action.

Brentuximab vedotin while Breastfeeding

Is it safe to take Brentuximab vedotin while breastfeeding?

Breastfeeding is not recommended during treatment with Brentuximab vedotin. While there is limited data on whether the drug passes into breast milk, the potential for serious adverse effects in a nursing infant cannot be ruled out. To ensure your baby’s safety, avoid breastfeeding during treatment and for at least 6 months after your last dose. If you are currently breastfeeding or planning to breastfeed, consult your healthcare provider to discuss alternative feeding options or treatment plans.

Estimated Cost of Brentuximab vedotin

The cost of Brentuximab vedotin can vary depending on factors such as your location, pharmacy, and insurance coverage. Without insurance, the estimated cost for a 30-day supply of Brentuximab vedotin using a GoodRx coupon ranges from approximately $10,000 to $15,000. Prices may fluctuate, so it is advisable to check with your pharmacy for the most up-to-date pricing. If the cost is a concern, speak with your healthcare provider or pharmacist about financial assistance programs or patient support services that may help reduce the expense of Brentuximab vedotin treatment.

Possible Alternatives to Brentuximab Vedotin Treatment

If Brentuximab vedotin is not the right treatment for you, or if you are exploring other options, there are several alternatives tailored to your specific condition. It is essential to consult your healthcare provider before making any changes to your treatment plan. You can also schedule a telemedicine appointment with one of our specialists to discuss your options in greater detail.

Hodgkin Lymphoma Treatment Alternatives

For Hodgkin lymphoma, alternative treatments include chemotherapy regimens such as ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) or radiation therapy. Additionally, immunotherapy drugs like nivolumab (Opdivo) and pembrolizumab (Keytruda) are emerging as promising options for certain patients.

Systemic Anaplastic Large Cell Lymphoma (ALCL) Alternatives

For systemic ALCL, alternative treatments may involve chemotherapy regimens such as CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone). In more aggressive cases, stem cell transplantation may be recommended to achieve better outcomes.

Peripheral T-Cell Lymphoma Options

Peripheral T-cell lymphoma can be managed with chemotherapy regimens like CHOP or ICE (Ifosfamide, Carboplatin, Etoposide). Participation in clinical trials may also provide access to innovative therapies that are not yet widely available.

Non-Hodgkin Lymphoma Treatment Options

For non-Hodgkin lymphoma, treatment options include chemotherapy, radiation therapy, targeted therapies such as rituximab (Rituxan), and immunotherapy. Your healthcare provider will work with you to determine the most effective approach based on your specific diagnosis and overall health.

Cutaneous T-Cell Lymphoma Alternatives

For cutaneous T-cell lymphoma, alternative treatments may include topical therapies, phototherapy, or systemic treatments such as interferon or retinoids. These options are carefully tailored to the stage and severity of the condition to ensure the best possible outcomes.

Relapsed or Refractory Hodgkin Lymphoma

In cases of relapsed or refractory Hodgkin lymphoma, high-dose chemotherapy followed by stem cell transplantation is a common approach. Immunotherapy with nivolumab (Opdivo) or pembrolizumab (Keytruda) may also be considered as part of the treatment plan.

Relapsed or Refractory Systemic ALCL

For relapsed or refractory systemic ALCL, stem cell transplantation or participation in clinical trials may offer alternative treatment options. These approaches aim to provide new hope for patients who have not responded to standard therapies.

Primary Mediastinal B-Cell Lymphoma Alternatives

Treatment for primary mediastinal B-cell lymphoma often involves chemotherapy regimens such as R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) or radiation therapy, depending on the stage and progression of the disease.

Diffuse Large B-Cell Lymphoma (DLBCL) Options

For diffuse large B-cell lymphoma, R-CHOP chemotherapy is a widely used treatment option. In cases where the disease has relapsed or is refractory, CAR T-cell therapy may be considered as an advanced treatment alternative.

Mantle Cell Lymphoma Treatment Alternatives

Mantle cell lymphoma can be treated with chemotherapy, targeted therapies such as ibrutinib (Imbruvica), and stem cell transplantation. Your healthcare provider will guide you in selecting the most appropriate treatment plan based on your individual needs and circumstances.

Recent Updates on Brentuximab Vedotin Research

Ongoing research on Brentuximab vedotin continues to explore its effectiveness and safety in treating various types of lymphoma. A significant focus is on combining Brentuximab vedotin with other immunotherapies or targeted therapies to improve outcomes for patients with relapsed or refractory lymphomas. These studies aim to enhance the drug’s efficacy and broaden its applications.

As of 2023, clinical trials are investigating the potential of combining Brentuximab vedotin with checkpoint inhibitors like nivolumab (Opdivo) or pembrolizumab (Keytruda). These combinations are designed to strengthen the immune system’s ability to fight cancer. While these trials are still ongoing, early results are encouraging. If you are interested in participating in a clinical trial, consult your healthcare provider or schedule a telemedicine consultation with one of our specialists to learn more about your options.

James Kingsley

Learn More